De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections


**Record Status**
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

**Bibliographic details**

**DOI**
10.3111/13696998.2013.839948

**Indexing Status**
Subject indexing assigned by NLM

**MeSH**
Antifungal Agents /administration & dosage /economics /therapeutic use; Candidiasis /drug therapy /economics /mortality; Cost-Benefit Analysis; Decision Support Techniques; Echinocandins /administration & dosage /economics /therapeutic use; Fluconazole /economics /therapeutic use; Health Services /economics /utilization; Humans; Life Expectancy; Lipopeptides /administration & dosage /economics /therapeutic use; Microbial Sensitivity Tests; Quality-Adjusted Life Years

**AccessionNumber**
22013049632

**Date bibliographic record published**
15/07/2014